Published in EMBO J on July 15, 1994
Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3. J Virol (1997) 4.26
Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol (1997) 3.88
B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J (1995) 2.51
Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol (1999) 2.41
The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J (1996) 2.27
The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol (1997) 2.24
An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe (2010) 2.23
Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol (2005) 2.08
A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate. Proc Natl Acad Sci U S A (1999) 1.90
Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol (1997) 1.89
The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol (1999) 1.81
Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol (1996) 1.71
Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol (1997) 1.64
The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. J Virol (1996) 1.61
RBP-J kappa repression activity is mediated by a co-repressor and antagonized by the Epstein-Barr virus transcription factor EBNA2. Nucleic Acids Res (1995) 1.61
Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation. J Virol (1997) 1.56
Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.54
A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J Virol (2000) 1.53
Retracted Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci U S A (1999) 1.52
Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses. J Virol (2000) 1.46
Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol (2004) 1.37
Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair (Amst) (2009) 1.37
Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J Virol (2000) 1.31
MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J Virol (2009) 1.31
Interaction of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) with HS1-associated protein X-1: implication of cytoplasmic function of EBNA-LP. J Virol (2000) 1.28
The Epstein-Barr virus and its association with human cancers. Mol Pathol (1999) 1.26
Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta. J Virol (1999) 1.24
Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J Exp Med (1997) 1.23
Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J (1995) 1.23
Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol (2004) 1.21
Cell cycle stage-specific phosphorylation of the Epstein-Barr virus immortalization protein EBNA-LP. J Virol (1996) 1.21
Signaling activities of gammaherpesvirus membrane proteins. J Virol (2000) 1.19
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol (2009) 1.18
Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol (2000) 1.16
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol (1995) 1.12
Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis. Proc Natl Acad Sci U S A (2002) 1.12
Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2. J Virol (2000) 1.12
The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol (2000) 1.12
Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol (2006) 1.10
Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol (1995) 1.09
Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol (2008) 1.08
Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol (2002) 1.08
Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency. Mol Cell Biol (1999) 1.08
Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog (2011) 1.07
Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol (2004) 1.05
Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol (1998) 1.05
Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J Virol (2001) 1.05
Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol (1999) 1.04
The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol (2000) 1.04
Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div (2009) 1.02
The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol (2007) 1.02
Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog (2013) 1.01
EBNA2 and activated Notch induce expression of BATF. J Virol (2003) 1.00
EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J Virol (2004) 1.00
E2F proteins are posttranslationally modified concomitantly with a reduction in nuclear binding activity in cells infected with herpes simplex virus 1. J Virol (2000) 1.00
Host factors LR1 and Sp1 regulate the Fp promoter of Epstein-Barr virus. Proc Natl Acad Sci U S A (1995) 0.97
The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J Virol (2005) 0.97
Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. Neoplasia (1999) 0.97
Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J Virol (2001) 0.96
Burkitt lymphoma: pathogenesis and immune evasion. J Oncol (2010) 0.96
Protein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins. Mol Cell Biol (2002) 0.96
EBNA-LP associates with cellular proteins including DNA-PK and HA95. J Virol (2001) 0.95
Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2. Proc Natl Acad Sci U S A (2013) 0.95
CD34+ cord blood cell-transplanted Rag2-/- gamma(c)-/- mice as a model for Epstein-Barr virus infection. Am J Pathol (2008) 0.95
Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathog (2013) 0.95
CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc Natl Acad Sci U S A (2003) 0.94
The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells. J Virol (2006) 0.93
Herpes simplex virus 1 mutant in which the ICP0 HUL-1 E3 ubiquitin ligase site is disrupted stabilizes cdc34 but degrades D-type cyclins and exhibits diminished neurotoxicity. J Virol (2003) 0.93
Epstein-Barr virus nuclear antigen leader protein induces expression of thymus- and activation-regulated chemokine in B cells. J Virol (2004) 0.92
Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A. J Virol (2007) 0.92
EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection. Front Genet (2013) 0.91
Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products. Int J Exp Pathol (2001) 0.90
Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. Adv Virus Res (2014) 0.86
Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells. J Virol (2001) 0.86
Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. J Virol (1996) 0.85
Upregulation of the cell-cycle regulator RGC-32 in Epstein-Barr virus-immortalized cells. PLoS One (2011) 0.85
Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity. EMBO J (1994) 0.84
CAK-independent activation of CDK6 by a viral cyclin. Mol Biol Cell (2001) 0.84
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res (2014) 0.84
EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance. J Virol (2004) 0.83
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PLoS One (2014) 0.81
C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog (2011) 0.81
Nuclear-cytoplasmic shuttling is not required for the Epstein-Barr virus EBNA-LP transcriptional coactivation function. J Virol (2009) 0.81
Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding. J Virol (2009) 0.80
Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells to Study Carcinogen Sensitivity and DNA Repair. Int J Mol Cell Med (2012) 0.80
Evolutionary aspects of oncogenic herpesviruses. Mol Pathol (2000) 0.79
Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. PLoS Pathog (2014) 0.79
Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency. J Virol (2013) 0.79
Epstein-Barr virus nuclear antigen 5 inhibits pre-mRNA cleavage and polyadenylation. Nucleic Acids Res (2002) 0.79
Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. Proc Natl Acad Sci U S A (2016) 0.79
Differential tumorigenicity between Epstein-Barr virus genome-positive and genome-negative cell lines with t(11;14)(q13;q32) derived from mantle cell lymphoma. J Virol (1996) 0.78
The effect of Epstein-Barr virus Latent Membrane Protein 2 expression on the kinetics of early B cell infection. PLoS One (2013) 0.78
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc Natl Acad Sci U S A (1981) 22.21
E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (1992) 10.28
Mammalian G1 cyclins. Cell (1993) 9.04
Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev (1993) 8.03
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 7.61
Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (1989) 7.60
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev (1993) 7.41
Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev (1993) 7.40
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell (1993) 7.19
Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell (1991) 6.65
Human acidic ribosomal phosphoproteins P0, P1, and P2: analysis of cDNA clones, in vitro synthesis, and assembly. Mol Cell Biol (1987) 5.63
Human D-type cyclin. Cell (1991) 5.47
Physical interaction of the retinoblastoma protein with human D cyclins. Cell (1993) 5.31
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell (1987) 3.87
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci (1993) 3.48
Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene (1993) 2.99
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol (1989) 2.98
Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol (1989) 2.86
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide. Proc Natl Acad Sci U S A (1986) 2.66
p53: oncogene or anti-oncogene? Genes Dev (1990) 2.60
Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci U S A (1990) 2.58
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol (1990) 2.58
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Characterization of a candidate bcl-1 gene. Mol Cell Biol (1991) 2.48
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Targets of cyclin-dependent protein kinases. Curr Opin Cell Biol (1993) 2.18
Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol (1989) 2.10
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A (1991) 2.04
B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med (1988) 2.00
Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics (1992) 1.99
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A (1993) 1.84
Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. Immunology (1986) 1.75
Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics (1992) 1.70
Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene (1993) 1.51
Cyclins and oncogenesis. Biochim Biophys Acta (1993) 1.41
Identification of sequences in Epstein-Barr virus DNA required for the expression of the second Epstein-Barr virus-determined nuclear antigen in COS-1 cells. J Gen Virol (1987) 1.40
Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene (1992) 1.40
Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene (1992) 1.40
Cell growth effects of Epstein-Barr virus leader protein. J Gen Virol (1992) 1.09
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur J Immunol (1990) 1.08
Transient expression of the CD2 cell surface antigen as a sortable marker to monitor high frequency transfection of human primary B cells. J Immunol (1991) 1.03
The Vin-1 gene, identified by provirus insertional mutagenesis, is the cyclin D2. Oncogene (1993) 1.01
Proviral insertions near cyclin D1 in mouse lymphomas: a parallel for BCL1 translocations in human B-cell neoplasms. Oncogene (1992) 1.00
Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system. Vaccine (1992) 0.82
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med (2001) 14.84
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell (1977) 6.22
FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol (1982) 6.11
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
Evidence for autolysin-mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface. Mol Microbiol (1997) 5.47
Adherence and growth of coagulase-negative staphylococci on surfaces of intravenous catheters. J Infect Dis (1982) 5.40
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (1995) 4.78
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta (1998) 4.45
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature (2001) 4.14
Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBO J (1986) 4.08
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res (1996) 3.89
Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell (1983) 3.89
A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J (1988) 3.69
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis (1998) 3.61
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
Microbial colonization of prosthetic devices. II. Scanning electron microscopy of naturally infected intravenous catheters. Zentralbl Bakteriol Mikrobiol Hyg B (1981) 3.53
Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature (1979) 3.43
A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J Bacteriol (1997) 3.25
Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon. Nature (1990) 3.19
Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill (2010) 3.15
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J Infect Dis (1988) 3.09
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Low-molecular-weight RNAs of Moloney murine leukemia virus: identification of the primer for RNA-directed DNA synthesis. J Virol (1977) 2.99
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol (1989) 2.98
Specific binding of tryptophan transfer RNA to avian myeloblastosis virus RNA-dependent DNA polymerase (reverse transcriptase). Proc Natl Acad Sci U S A (1975) 2.97
Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol (1985) 2.82
Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis. Clin Infect Dis (1997) 2.82
Interference with granulocyte function by Staphylococcus epidermidis slime. Infect Immun (1986) 2.80
Intravenous cefotaxime in children with bacterial meningitis. Lancet (1980) 2.77
Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. EMBO J (1984) 2.77
Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol (2001) 2.66
A 140-kilodalton extracellular protein is essential for the accumulation of Staphylococcus epidermidis strains on surfaces. Infect Immun (1997) 2.65
Rapid and specific detection of toxigenic Staphylococcus aureus: use of two multiplex PCR enzyme immunoassays for amplification and hybridization of staphylococcal enterotoxin genes, exfoliative toxin genes, and toxic shock syndrome toxin 1 gene. J Clin Microbiol (1998) 2.60
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene (1994) 2.55
Staphylococcus aureus RN6390 replicates and induces apoptosis in a pulmonary epithelial cell line. Infect Immun (2000) 2.54
Potential oncogene product related to growth factors. Nature (1987) 2.53
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol (1998) 2.42
Effect of extracellular slime substance from Staphylococcus epidermidis on the human cellular immune response. Lancet (1984) 2.35
Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology (1987) 2.32
Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J (1995) 2.26
The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene (1991) 2.25
Concerted activation of two potential proto-oncogenes in carcinomas induced by mouse mammary tumour virus. Nature (1986) 2.24
Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci U S A (1978) 2.22
D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene (1991) 2.21
Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg (2005) 2.19
Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with darier's disease. Clin Infect Dis (2001) 2.14
Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood (2000) 2.12
Cyclin D1 and prognosis in human breast cancer. Int J Cancer (1996) 2.11
Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells. Infect Immun (2000) 2.11
Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature (1997) 2.10
Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phenotypes. Infect Immun (2002) 2.08
Expression of the FGF-related proto-oncogene int-2 during gastrulation and neurulation in the mouse. EMBO J (1988) 2.08
Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene (1994) 1.99
Homologous upstream sequences near Epstein-Barr virus promoters. Proc Natl Acad Sci U S A (1983) 1.98
Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol (1990) 1.97
Microbial colonization of prosthetic devices. III. Adhesion of staphylococci to lumina of intravenous catheters perfused with bacterial suspensions. Zentralbl Bakteriol Mikrobiol Hyg B (1981) 1.97
Pathogenesis and management of Staphylococcus epidermidis 'plastic' foreign body infections. J Antimicrob Chemother (1984) 1.96
Microbial colonization of prosthetic devices. I. Microtopographical characteristics of intravenous catheters as detected by scanning electron microscopy. Zentralbl Bakteriol Mikrobiol Hyg B (1981) 1.95
Sequence analysis of Raji Epstein-Barr virus DNA. Virology (1988) 1.95
Retracted Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet (1989) 1.94
RNA-directed DNA synthesis in Moloney murine leukemia virus: interaction between the primer tRNA and the genome RNA. J Virol (1979) 1.92
Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene. Mol Cell Biol (1986) 1.90
Complex structure and regulation of the P16 (MTS1) locus. Cancer Res (1995) 1.87
Protein-coding potential of mouse mammary tumor virus genome RNA as examined by in vitro translation. J Virol (1981) 1.87
The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J (1990) 1.82
Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis (1998) 1.81
Systematic literature analysis and review of targeted preventive measures to limit healthcare-associated infections by meticillin-resistant Staphylococcus aureus. Euro Surveill (2014) 1.79
Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology (1990) 1.78
In vitro synthesis of polypeptides encoded by the long terminal repeat region of mouse mammary tumour virus DNA. Nature (1981) 1.77
Chromosome 11q13 abnormalities in human cancer. Cancer Cells (1991) 1.74
Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseINT system into two macromolecular components; role of a small molecule in nuclease activation. Biochem Biophys Res Commun (1978) 1.70
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology (2011) 1.70
alpha-Toxin is a mediator of Staphylococcus aureus-induced cell death and activates caspases via the intrinsic death pathway independently of death receptor signaling. J Cell Biol (2001) 1.67
Multiple RNAs expressed from the int-2 gene in mouse embryonal carcinoma cell lines encode a protein with homology to fibroblast growth factors. EMBO J (1988) 1.66
A standardized nomenclature for endogenous mouse mammary tumor viruses. J Virol (1987) 1.65
Small colony variants in staphylococcal infections: diagnostic and therapeutic implications. Clin Infect Dis (1998) 1.64
Mouse mammary tumor virus integration regions int-1 and int-2 map on different mouse chromosomes. Mol Cell Biol (1984) 1.64
Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol (2000) 1.64
Investigations on staphylococcal infection of transvenous endocardial pacemaker electrodes. Am Heart J (1984) 1.63
Mapping of the gene coding for Epstein-Barr virus-determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector. J Virol (1987) 1.61
Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol (1994) 1.60
Comparative analysis of a biofilm-forming Staphylococcus epidermidis strain and its adhesion-positive, accumulation-negative mutant M7. FEMS Microbiol Lett (1994) 1.60
The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol (1989) 1.59
Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol (2000) 1.57
New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis (1999) 1.57
Identification and characterization of a novel 38.5-kilodalton cell surface protein of Staphylococcus aureus with extended-spectrum binding activity for extracellular matrix and plasma proteins. J Bacteriol (2001) 1.56
tRNA's and priming of RNA-directed DNA synthesis in mouse mammary tumor virus. J Virol (1980) 1.56
Mouse mammary tumor virus can mediate cell fusion at reduced pH. Virology (1984) 1.56
In-vitro efficacy of a central venous catheter ('Hydrocath') loaded with teicoplanin to prevent bacterial colonization. J Hosp Infect (1992) 1.55
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55